These 2 'Strong Buy' Penny Stocks Could Go Boom, Say Analysts
MDxHealth Expands Prostate Cancer Test Portfolio
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
MDxHealth (MDXH) Gets a Buy From BTIG
These Analysts Increase Their Forecasts On MDxHealth After Q4 Results
MDxHealth SA (NASDAQ:MDXH) reported better-than-expected sales for its fourth quarter on Wednesday. MDxHealth posted quarterly GAAP loss of 39 cents per share, compared to market expectations for a l
MDxHealth Price Target Raised to $7.00/Share From $6.00 by Piper Sandler
MDxHealth Price Target Raised to $7.00/Share From $6.00 by Piper Sandler
Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth Is Maintained at Buy by BTIG
MDxHealth Is Maintained at Buy by BTIG
BTIG Maintains Buy on MDxHealth, Raises Price Target to $8
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and raises the price target from $7 to $8.
MDxHealth Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 105.13% BTIG $7 → $8 Maintains Buy 11/09/2023 53.85% Piper Sandler $10 → $6 Maintains Overweigh
Earnings Call Summary | MDxHealth(MDXH.US) Q4 2023 Earnings Conference
The following is a summary of the MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript:Financial Performance:MDxHealth reported a Q4 revenue of $19.4 million, a 50% increase compared to Q4 2022, and t
Buy Rating Affirmed for MDxHealth Amid Strong Q4 Performance and Positive Future Outlook
MDxHealth Q4 2023 GAAP EPS $(0.390) Misses $(0.150) Estimate, Sales $19.398M Beat $18.136M Estimate
MDxHealth (NASDAQ:MDXH) reported quarterly losses of $(0.390) per share which missed the analyst consensus estimate of $(0.150) by 160 percent. The company reported quarterly sales of $19.398 million
Earnings Flash (MDXH) MDXHEALTH Posts Q4 Revenue $19.4M
04:02 PM EST, 03/06/2024 (MT Newswires) -- Earnings Flash (MDXH) MDXHEALTH Posts Q4 Revenue $19.4M
MDxHealth: Confirms Its View of Expected Adjusted EBITDA Profitability in the 1H of 2025 >MDXH
MDxHealth: Confirms Its View of Expected Adjusted EBITDA Profitability in the 1H of 2025 >MDXH
MDxHealth Backs 2024 Rev $79M-$81M >MDXH
MDxHealth Backs 2024 Rev $79M-$81M >MDXH
MDxHealth 4Q Loss $10.7M >MDXH
MDxHealth 4Q Loss $10.7M >MDXH
Press Release: Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding G
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. • Foot Locker (NYSE:FL) is likely to report quarterly e
No Data